Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf

Fig. 2

PPL008-C/N dose response in MM415 (NRAS Q61L) human malignant melanoma cell line. a & b: Normalised pERK expression (mean ± SEM) in MM415 cells following dose response co-treatment with PLX4032 (1 μM) and PPL-008 N or PPL-008C (1 nM – 10 μM). Respective pERK and GAPDH immunoblot examples shown below. (N = 3, * P < 0.05, ** P < 0.01, *** P < 0.001), DMSO vs. PPL008 only, PLX vs. PLX + PPL008). c & d (i) Real-time cell analyses (xCELLigence platform) of MM415 cell proliferation following dose response co-treatments with PPL-008 N or PPL-008C (1 nM - 10 μM) and PLX4032 (1 μM). Treatments occurred at 32 h and the slope of normalised cell index (mean ± STDEV) was measured between 32 and 48 h (n = 3, *** P < 0.001). c & d (ii) Representative traces of normalised cell index of each treatment shown below. N, PPL-008 N; C, PPL-008C

Back to article page